Cite

    Amin, A., Keshishian, A., Hines, D. M., Dina, O., Le, H., Rosenblatt, L., Liu, X., Zhang, Q., & Vo, L. (2022). risk of stroke/systemic embolism, major bleeding, and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran, or rivaroxaban compared with warfarin in the United States medicare population: updated analysis. Current medical research and opinion, 38, 2131–2140. http://access.bl.uk/ark:/81055/vdc_100171889569.0x00004a